What's Happening?
Recursion, a techbio company based in Salt Lake City, recently hosted an event where Jenny Jones, a patient advocate, shared her family's history with familial adenomatous polyposis (FAP), a rare genetic disease. FAP causes noncancerous polyps to develop
in the colon and rectum, which can turn cancerous if untreated. Jenny's family has a long history with FAP, tracing back to her great grandparents. Her mother, diagnosed with colorectal cancer at 34, underwent multiple surgeries and eventually succumbed to the disease. Jenny herself was diagnosed at 8 and has undergone several surgeries, including the removal of her colon. Despite these challenges, she founded 'Life’s a Polyp' to raise awareness about FAP. Recursion is currently testing a treatment, REC-4881, which aims to reduce polyp burden in FAP patients.
Why It's Important?
The event underscores the importance of continued research and development in rare diseases like FAP. Recursion's work could lead to significant advancements in treatment, potentially improving the quality of life for patients with FAP. The story of Jenny Jones highlights the challenges faced by those with rare diseases, including delayed diagnosis and inadequate medical surveillance. By sharing her experience, Jenny brings attention to the need for better diagnostic tools and treatments. Recursion's efforts in developing REC-4881, which has shown promising early results, could pave the way for more effective management of FAP, offering hope to patients and their families.
What's Next?
Recursion's REC-4881 is currently in Phase 2 testing, with early data indicating a reduction in polyp burden. The company will continue its research to further validate these findings and potentially bring the treatment to market. The biotech community and patient advocacy groups will likely monitor these developments closely, as successful outcomes could influence future research directions and funding allocations for rare diseases. Additionally, Jenny Jones' advocacy work may inspire other patients to share their stories, further raising awareness and support for rare disease research.
Beyond the Headlines
The story of Jenny Jones and her family's battle with FAP highlights broader issues in healthcare, such as the need for improved genetic screening and patient education. It also raises ethical questions about family planning decisions in the context of hereditary diseases. Jenny's decision not to have biological children to end the cycle of FAP in her family is a poignant example of the difficult choices faced by those with genetic disorders. This narrative may prompt discussions on genetic counseling and the role of patient advocacy in shaping healthcare policies.
